flavin-mononucleotide and Poisoning

flavin-mononucleotide has been researched along with Poisoning* in 4 studies

Trials

1 trial(s) available for flavin-mononucleotide and Poisoning

ArticleYear
[Effect of cytoflavin on some physiological values in patients with toxicohypoxic encephalopathy].
    Eksperimental'naia i klinicheskaia farmakologiia, 2013, Volume: 76, Issue:11

    The effect of cytoflavin upon bolus intravenous administration on the state of hemodynamic values and liquid sectors of the organism was studied in patients with toxicohypoxic encephalopathy caused by heavy acute poisoning. It is established that the bolus administration of cytoflavin is less effective than dropwise intravenous injection.

    Topics: Acute Disease; Adult; Brain Diseases, Metabolic; Drug Combinations; Female; Flavin Mononucleotide; Hemodynamics; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Poisoning; Succinates

2013

Other Studies

3 other study(ies) available for flavin-mononucleotide and Poisoning

ArticleYear
[Immune system disorders and their correction in critically ill patients with toxic and hypoxic encephalopathy].
    Georgian medical news, 2012, Issue:203

    In this article there are materials, which were received in the process of treatment of 69 patients with azaleptin (leponeks) acute severe poisonings. The immunologic research has shown that the first phase of acute poisonings in patients with toxicohypoxic encephalopathy is accompanied by severe immune alterations. The alterations of proinflammation and antiinflammation cytokines have been investigated and its increase has not been revealed. It was shown, that the employment of citoflavin in intensive therapy of acute poisonings leads to decrease of the level of immunosupression.

    Topics: Blood Cell Count; Clozapine; Critical Illness; Drug Combinations; Female; Flavin Mononucleotide; Humans; Hypoxia, Brain; Immune System; Inosine Diphosphate; Male; Neurotoxicity Syndromes; Niacinamide; Poisoning; Succinates

2012
[Methods for the prevention and treatment of toxico-hypoxic encephalopathy in patients with acute severe poisoning].
    Klinicheskaia meditsina, 2011, Volume: 89, Issue:6

    The study included 147 patients with toxico-hypoxic encephalopathy resulting from acute poisoning. It was shown that intensive therapy with cytoflavin (20 ml in 400 ml of 5% glucose solution twice daily for 7 days) reduced severity of hypoxic brain lesions and suppression of CNS as apparent from the improvement of its bioelectric activity. The recovery of CNS regulatory action on the life-sustaining systems of the body promoted normalization of the respiratory component of oxygen transport. The improvement of the patients' conditions in the acute phase contributed to accelerated recovery of cognitive-amnestic functions and social adaptation. Cytoflavin therapy improved the clinical picture of toxico-hypoxic encephalopathy due to the reduction in the duration of the comatose state from 45.3 +/- 8.2 to 27.7 +/- 6.9 hr and the decrease in the frequency of secondary pulmonary complications from 72.7 to 35.9%.

    Topics: Acute Disease; Adult; Antidotes; Drug Combinations; Electroencephalography; Flavin Mononucleotide; Humans; Hypoxia, Brain; Inosine Diphosphate; Neuroprotective Agents; Niacinamide; Poisoning; Severity of Illness Index; Succinates; Vitamin B Complex

2011
[The use of cytoflavin in combined neurometabolic therapy of acute cerebral insufficiency associated with acute poisoning with neurotropic poisons].
    Klinicheskaia meditsina, 2010, Volume: 88, Issue:2

    Examination and treatment of 262 patients with severe acute intoxication by neurotropic poisons and unaffected oxygen delivery system showed that inclusion of cytoflavin in combined neurometabolic therapy of acute cerebral insufficiency significantly reduced severity of metabolic disorders. Specifically, tissue hypoxy, endotoxicosis, lipid peroxidation activity, and immunosuppression decreased while antioxidative protection and clinical picture were improved. Duration of comatose state and artificial lung ventilation was reduced from 64.5 +/- 15.1 to 28.8 +/- 10.2 hours and that of critical condition from 117.2 +/- 17.2 to 63.7 +/- 9.2 hours. Overall lethality dropped from 16 to 9.9%.

    Topics: Acute Disease; CD3 Complex; CD4 Antigens; CD8 Antigens; Coma; Critical Illness; Drug Combinations; Flavin Mononucleotide; Humans; Hypoxia, Brain; Inosine Diphosphate; Lymphocytes; Neuroprotective Agents; Neurotoxicity Syndromes; Niacinamide; Poisoning; Receptors, Interleukin-2; Respiration, Artificial; Succinates

2010